Can corporations be compassionate? Rice University researchers are figuring that out. Pexels

Since the early 2000s, the business of doing business has changed its looks markedly. As corporations gain power and reach, many in the public are subjecting them to increasingly insistent questions about their impact on the lives of workers, the environment and society at large.

At the same time, academics have focused more attention on compassion in management and business organizations. Today, considerable research parses the way corporate conduct affects employees, laid-off workers and the well-being of society as a whole. A considerable segment of this academic literature advocates for what once seemed like an oxymoron: compassion in corporate management.

Most of the recent research on compassion focuses on individuals and the group. Most management research, meanwhile, centers on economic performance and efficiency. In an editorial for Journal of Management, though, Rice Business Mary Gibbs Jones Professor Emeritus of ManagementJennifer George argues that compassion research can actually be a jumping-off point for focus on social problems, well-being and identifying the conditions under which organizations do the least harm.

But what is compassion in business, exactly? According to George, it's the practice of setting up organizations so that they respond to the vulnerable groups in their orbit. To do this, George says, companies should reconsider the concept of "American Corporate Capitalism (ACC)," which operates when corporations, workers and consumers pursue self-interest. ACC follows the laws of supply and demand, and is founded on the bedrock principles of respect for private property, an emphasis on economic growth and using profits as the measuring stick for making business decision.

Make no mistake, George adds: "ACC is an ideology." A host of institutions provide the underpinnings that allow ACC to flourish, among them the legal system, governmental agencies, stock markets, media and advertising and trade organizations.

But, notes George, the rewards from American Corporate Capitalism are narrowing sharply. ACC, she contends, now concentrates benefits upon fewer and fewer people. One article she cites suggests that outsized CEO salaries and compensation, coupled with large income inequality within a company, may result in organizations that do harm to their workers.

In fact, "the tenets of ACC seem to downplay the importance of compassionate organizing," says George. Harm done by corporations, such as laying off employees, may occur unintentionally, but those decisions still cause suffering. ACC, she says, "has the potential to create conditions under which compassion is much less likely to occur."

As a result, it's crucial to closely examine the tensions and contradictions between ACC and compassion. A focus on compassion would "identify the conditions under which organizations inflict the least harm and alleviate the most suffering," George writes.

She proposes a wide-ranging agenda to achieve this. First, researchers should look at organizational decision-making to track the influence of ACC values and whether criteria such as dominance or hierarchy override harmony and egalitarianism. Identifying the factors that spur organizations to favor only shareholders and customers over employees and neighboring communities could offer insights for management. Other research, George suggests, ought to examine a range of companies operating in the same sector, tracing which cause more damage and which are more successful at reducing suffering.

Finally, George says, academics should develop case studies of organizations that successfully pursue policies such as employing the disabled – policies designed to promote the well-being of vulnerable groups inside and outside the company.

Because corporations wield such vast influence, the harm they do can reach wide swaths of the population. It's time, George writes, for researchers to examine the disconnects between prevailing corporate culture and compassion. Effectively done, she says, such research could vault over the ivory battlements into the heart of everyday life.

------

This story originally ran on Rice Business Wisdom in 2019.

Based on research from Jennifer M. George, the Mary Gibbs Jones Professor Emeritus of Management in Organizational Behavior at the Jones Graduate School of Business at Rice University.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.